Timothy Rolph Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of the business's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $51.09, for a total transaction of $638,625.00. Following the sale, the insider owned 167,124 shares in the company, valued at $8,538,365.16. The trade was a 6.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Timothy Rolph also recently made the following trade(s):

• On Wednesday, June 18th, Timothy Rolph sold 1,129 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.84, for a total transaction of $61,914.36.
• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $127,332.00.
• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.49, for a total transaction of $668,625.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.04, for a total transaction of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.43, for a total transaction of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.03, for a total transaction of $256,437.50.

Akero Therapeutics Trading Up 1.4%

Shares of NASDAQ AKRO traded up $0.71 on Thursday, reaching $51.84. 330,780 shares of the company traded hands, compared to its average volume of 1,051,302. Akero Therapeutics, Inc. has a fifty-two week low of $21.34 and a fifty-two week high of $58.40. The company has a 50 day moving average of $49.32 and a 200 day moving average of $43.18. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $4.13 billion, a PE ratio of -26.52 and a beta of -0.15.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. On average, equities research analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Trading of Akero Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AKRO. RTW Investments LP increased its position in Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after purchasing an additional 940,388 shares in the last quarter. Deep Track Capital LP grew its position in Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock valued at $41,452,000 after acquiring an additional 800,216 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in Akero Therapeutics in the fourth quarter valued at approximately $18,059,000. SG Americas Securities LLC grew its position in Akero Therapeutics by 93.3% in the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after acquiring an additional 557,794 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in Akero Therapeutics in the first quarter valued at approximately $21,333,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on AKRO. Bank of America boosted their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. Citigroup cut their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $82.50.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.